FR3006587A1 - COMPOSITION FOR CORRECTING SKIN DYSCHROMY AND IMPROVING THE HOMOGENEITY OF THE DYE - Google Patents

Abstract

The present invention relates to a cosmetic composition for correcting cutaneous dyschromias, such as pigmentary spots and / or redness, and to homogenize and lighten the complexion.

Description

The present invention relates to a composition intended to correct cutaneous dyschromias, such as pigmentary spots, and to homogenize the complexion. The skin, and more particularly the skin of the face, can experience variations in texture and color, resulting in particular in skin dyes and an inhomogeneous complexion that can be unsightly. Many external or internal factors can affect the uniformity of the skin's complexion. Extrinsic factors include exposure to changes in temperature and humidity or exposure to pollutants. Among the intrinsic factors affecting the uniformity of skin tone are stress, fatigue, hormonal changes, dehydration of the skin or an alteration of the barrier function of the skin, or even aging. These extrinsic and intrinsic factors tend to blur the complexion, to make it inhomogeneous, dull, waxy and to promote the presence of cutaneous imperfections. The skin may also be subject to color variations, known as skin dychromas. Among the cutaneous dyschromias, one distinguishes in particular the brown pigmentary spots and the rednesses. The sun and cutaneous aging can cause a change in the distribution of melanin, the pigment at the origin of the color of the skin. The latter is distributed in the skin irregularly, forming tasks. These brown pigment spots and redness are unsightly and detract from the radiance and homogeneity of the complexion. There is therefore a real need to be able to prevent, reduce or eliminate these alterations of texture and color of the skin, so as to obtain a uniform skin tone. A homogeneous complexion of the skin, in particular of the skin of the face, accentuates the radiance of the complexion and provides a "good looking" effect sought by the consumer. The object of the present invention is to provide a composition, in particular a cosmetic composition, intended to improve the complexion, more particularly to homogenize and / or brighten the complexion of the skin. The object of the present invention is to provide a composition, in particular a cosmetic composition, making it possible to prevent and / or to reduce and / or correct skin problems.

The present invention also aims to provide a composition, including cosmetic, to correct dyschromias and / or improve the complexion and whose effects on the skin persist after stopping its application. The present invention aims to provide a cosmetic treatment method comprising the application on the skin of a composition according to the invention. Thus, the present invention relates to a composition comprising: at least one C-glucoside derivative of formula (I) as described below; at least one phenoxypropionic acid derivative of formula (II) as described below; at least salicylic acid or a compound of formula (III) as described below; acetyl 15-tetrapeptide; an extract of Grifola frondosa; and an extract of Chlorella. According to a particular embodiment, the composition comprises: C-beta-D-xylopyranoside-2-hydroxy-propane; 2- (4-hydroxyphenoxy) propionic acid; n-octanoyl-5-salicylic acid; acetyl 15-tetrapeptide; an extract of Grifola frondosa; - an extract of Chlorella vulgaris; and a physiologically acceptable medium. According to one embodiment, the composition according to the invention is a cosmetic composition. Surprisingly, the inventors have discovered that a composition comprising the active ingredients as defined below makes it possible to homogenize and / or brighten the complexion, and more particularly to prevent and / or reduce and / or correct 30 the cutaneous dyschromias. According to one embodiment, the composition according to the invention makes it possible: to lighten the cutaneous dyschromias, and / or to lighten the areas adjacent to the cutaneous dyschromias, and / or to reduce the contrast between the cutaneous dyschromias and the normal color of the skin, and / or - decrease the surface of the cutaneous dyschromias. According to one embodiment, the dyschromias are brown pigmented spots, also called hyperpigmentation patches, for example senile lentigines, and redness, in particular diffuse redness.

According to another embodiment, the composition according to the invention makes it possible: to improve the homogeneity of texture and color of the skin, and / or to make the skin thinner and having a more even surface, and or - to lighten the skin, and / or - to reduce skin tones due to hemoglobin (such as diffuse redness) and / or melanin (such as hyperpigmentation). According to one embodiment, the composition according to the invention makes it possible to reduce the red and yellow tones of the skin so as to lighten it. According to another embodiment, the composition according to the invention makes it possible to refine the skin texture and / or correct the surface irregularities of the skin.

Even more surprisingly, the effects of the composition are persistent after stopping its use, especially several weeks after stopping its application, especially until at least 5 weeks after stopping its application. Thus, according to one embodiment, the effects of the composition according to the invention persist after stopping its application.

According to one embodiment, the composition according to the invention does not contain a sunscreen. "Cosmetic composition" is understood to mean a substance or a preparation intended to be brought into contact with the various superficial parts of the human body, in particular the epidermis, the hair and hair systems, the nails, the lips and the external genital organs, or with the teeth and mucous membranes of the mouth, with a view, exclusively or mainly, to clean, perfume, modify the appearance, protect, maintain or repair body odors. A cosmetic composition is intended for non-therapeutic use.

A cosmetic composition is for non-therapeutic use. The cosmetic composition may be intended to be applied to the skin or superficial body growths, preferably to the skin. By "skin" is meant the skin of the face and / or the body, the scalp and the semi-mucous membranes (lips), more particularly the skin of the face, such as the skin of the cheeks and / or the forehead, and the skin. skin of the hands.

"Dander" means hair, hair, eyelashes, nails. "The homogeneity of the complexion" corresponds to the uniformity of color and texture of the skin. The uniformity of texture corresponds to a regular grain of skin, to the absence of imperfection or surface defect. "Skin texture" refers to the appearance and / or the size of the pores of the skin, as well as to the skin microrelief. The uniformity of color corresponds to a uniform skin color over the entire cutaneous zone envisaged, in particular the face. According to one embodiment, the uniformity of color corresponds to the absence or reduction of cutaneous dyschromias. "Dyschromia" is understood to mean any aesthetic modification of the skin color whether it is hyper and / or hypopigmentation of the skin. The pigmentation may for example be excessive, localized or generalized. The present invention also relates to the cosmetic use of the composition according to the invention. According to one embodiment, the composition according to the invention is used for the care of the skin, preferably the care of the skin of the face. According to another embodiment, the composition is used to improve the homogeneity of the complexion and / or lighten the complexion. According to one embodiment, the composition according to the invention is used for preventing and / or reducing and / or correcting cutaneous dyschromias.

According to a particular embodiment, the composition is used for lightening and / or reducing the surface of cutaneous dyschromias. According to one embodiment, the composition is used to reduce the contrast between the zone of dyschromia and the normal color of the skin. By "decrease the contrast" is meant the decrease in the color difference between the area of dyschromia and the normal color of the skin. According to one embodiment, the evaluation of the contrast reduction can be performed by instrumental measurements that can be made using equipment called Sciascope®, which allows the specific evaluation of the amount of melanin and therefore of the colon intensity of a task and its adjacent area. It is accepted that for a variation, even statistically significant, of less than one unit of measurement, the human eye is not able to perceive this improvement. The cosmetic composition according to the invention is also intended to be used for refining the skin texture and / or reducing and / or correcting surface irregularities of the skin. According to one embodiment, the composition according to the invention is intended for topical application.

According to one embodiment, the composition according to the invention comprises at least each of the different types of active ingredients detailed below. The amounts of active ingredients are given in percentage by weight of active ingredient relative to the total weight of the composition.

Derivatives C-glycoside: The C-glycoside derivatives are advantageously endowed with the property of exerting their hygroscopic effects on the skin and not in the cosmetic composition. Advantageously, a cosmetic composition comprising a C-glycoside derivative can exert a long-term care action, even after its removal from the tissues. The C-glycoside derivatives that are suitable for the invention have the following general formula (1): ## STR2 ## in which: R denotes an unsubstituted linear C1-C4, in particular C1-C2, alkyl radical, in particular methyl; S represents a monosaccharide selected from D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, and especially D-xylose; X represents a group chosen from -CO-, -CH (OH) -, -CH (NH 2) -, and preferentially a -CH (OH) - group, by way of non-limiting illustration of the C-glycoside derivatives which are more particularly suitable for the invention may especially be mentioned as follows: C-beta-D-xylopyranoside-n-propan-2-one, C-alpha-D-xylopyranoside-n-propan-2-one, C-beta-D-xylopyranoside-2-hydroxy-propane, C-alpha-D-xylopyranoside-2-hydroxy-propane, 1- (C-beta-D-glucopyranosyl) -2-hydroxypropane; 1- (C-alpha-D-glucopyranosyl) -2-hydroxypropane; - (C-beta-D-glucopyranosyl) -2-amino-propane; 1- (C-alpha-D-glucopyranosyl) -2-amino-propane; 3 '- (acetamido-C-beta-D-glucopyranosyl) propan-2'-one; 3 '- (acetamido-C-alpha-D-glucopyranosyl) propan-2'-one; 1- (acetamido-C-beta-D-glucopyranosyl) -2-hydroxylpropane; 1- (acetarnido-C-beta-D-glucopyranosyl) -2-amino-propane; their isomers and mixtures thereof.

According to one embodiment, C-beta-D-xylopyranoside-2-hydroxy-propane or C-alpha-D-xylopyranoside-2-hydroxy-propane, and best C-beta-D-xylopyranoside-2-hydroxy- propane can advantageously be used for the preparation of a composition according to the invention. According to a particular embodiment, a C-glycoside derivative that is suitable for the invention may advantageously be hydroxypropyl-tetrahydropyrantriol also called C-beta-D-xylopyranoside-2-hydroxypropane, in particular proposed in solution at 30% by weight. in a mixture of water / propylene glycol 60/40 (vlv) under the name MEXORYL SBB® by CH1MEX. According to one embodiment, the C-glycoside derivative is in the form of a solution in which it is present in an amount of 30% by weight relative to the total weight of the solution, the remainder being a mixture of water and propylene glycol. According to one embodiment, the C-glycoside derivatives corresponding to formula (I) may be of natural or synthetic origin, totally or partially purified, or any preparation containing them.

By natural origin is meant a C-glycoside derivative extracted from a natural material in which it is present, for example plants. By synthetic origin is meant a C-glycoside derivative prepared by chemical synthesis or by biotechnology. The term "totally or partially purified" means here that, during its synthesis or in relation to its natural state (fresh or dried plant or cells), a C-glycoside derivative corresponding to formula (I) has been concentrated and / or disposed of, respectively, at least a portion of the secondary reaction products from its synthesis or at least a portion of the other constituents of the natural material in which it is present.

The salts of the C-glycoside derivatives suitable for the invention may comprise conventional physiologically acceptable salts of these compounds such as those formed from organic or inorganic acids. By way of example, mention may be made of mineral acid salts, such as sulfuric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid and boric acid. Mention may also be made of organic acid salts, which may comprise one or more carboxylic acid, sulphonic acid or phosphonic acid groups. It may be linear, branched or cyclic aliphatic acids or aromatic acids. These acids may furthermore comprise one or more heteroatoms chosen from O and N, for example in the form of hydroxyl groups. These include propionic acid, acetic acid, terephthalic acid, citric acid and tartaric acid. When a C-glycoside derivative has at least one acid group, the neutralization of the acid group or groups may be carried out with a mineral base, such as LiOH, NaOH, KOH, Ca (OH) 2, NH 4 OH, Mg (OH) 2 or Zn (OH) 2; or by an organic base such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine. This primary, secondary or tertiary alkylamine may comprise one or more nitrogen and / or oxygen atoms and may therefore comprise, for example, one or more alcohol functions; mention may especially be made of amino-2-methyl-2-propanol, triethanolamine, dimethylamino-2-propanol and 2-amino-2- (hydroxymethyl) -1,3-propanediol. Mention may also be made of lysine or 3- (dimethylamino) propylamine.

Acceptable solvates for the compounds described above include conventional solvates such as those formed in the last step of preparing said compounds due to the presence of solvents. By way of example, mention may be made of solvates due to the presence of water or of linear or branched alcohols, such as ethanol or isopropanol.

A C-glycoside derivative that is suitable for the invention may in particular be obtained by the synthesis method described in WO 02/051828, the contents of which are incorporated herein by reference. According to one embodiment, the composition according to the invention comprises a C-glycoside derivative in a proportion of about 1% to about 30% by weight of active ingredient (C-glycoside derivative) relative to the total weight of the composition, in particular from about 2% to about 20% by weight of active material relative to the total weight of the composition, more particularly from about 2.5% to about 15% by weight of active ingredient relative to the total weight of the composition and more particularly from about 7% to about 11% by weight of active material, for example about 9% by weight of active material. . Phenoxypropionic Acid Derivatives: The compositions according to the invention comprise at least one compound of formula (II) below: ## STR1 ## in which: WY is chosen from H, an alkyl or alkenyl group comprising from 1 to 8 carbon atoms phenyl, Na, e or NH4 +; Ry is chosen from H, a linear or branched, saturated or unsaturated alkyl group comprising from 1 to 18 carbon atoms, a -C (= O) -Rz group, in which Rz is a linear or branched, saturated or unsaturated alkyl group; comprising 1 to 17 carbon atoms or a group - (CF12), - COORw in which n is between 0 and 17, Rw is chosen from H, an alkyl or alkenyl group comprising from 1 to 8 carbon atoms, a phenyl Na +, e or NH4 +; or one of its organic or inorganic base salts, or one of its enantiomers.

According to a particular embodiment, the compound of formula (II) is characterized in that Y is chosen from the group consisting of H, methyl, ethyl, isopropyl, Na + and K. According to another particular embodiment, the compound of formula (II) is characterized in that Ry is selected from the group consisting of H, a linear or branched, saturated or unsaturated alkyl group comprising from 1 to 18 carbon atoms and a group - (CH2) n-COORw in which n is 0, 1 or 2 and Rw is H. According to a preferred embodiment, the compound of formula (II) is characterized in that Ry is methyl and Y is H: it is acid ( 4-hydroxy-phenoxy) -propionic acid.

2- (4-hydroxy-phenoxy) -propionic acid, of which the CAS number is 67648-61-7, also called HPPA, is a hydroquinone ether of structural formula: OH OH This compound is especially sold by Sigma Aldrich or can be obtained by preparative methods known to those skilled in the art, by organic chemistry reactions or by microbial or enzymatic hydroxylation of the phenoxy group. The preparation of this compound is generally described in the patent application EP 0 334 595. The compounds of formula (II), in particular 2- (4-hydroxyphenoxy) -propionic acid, are described in the patent application WO 2008 / 107092. 2- (4-hydroxy-phenoxy) -propionic acid comprises an asymmetric carbon and can therefore be in the racemic form or in the enantiomeric form R or S. In the context of the present invention, the term "acid 2- (4-hydroxy-phenoxy) -propionic acid ", 2- (4-hydroxy-phenoxy) -propionic acid in racemic form, or in its enantiomeric form R, is acid (R) - (+) - 2- (4-hydroxy-phenoxy) -propionic acid. 2- (4-hydroxy-phenoxy) -propionic acid is preferably white in color. It is marketed under the reference RADIANSKIN PW LS 9918 from 15 Laboratoires Sérobiologiques and / or COGNIS and / or BASF (consecutive purchases) 100% active ingredient. According to one embodiment, the composition according to the invention comprises a phenoxypropionic acid derivative in a proportion of about 0.1% to about 10% by weight of active material (derived from phenoxypropionic acid), in particular from about 0.25% to about 5% by weight of active material, in particular from about 0.5% to about 1.5% by weight of active material relative to the total weight of the composition, for example about 1 % by weight of active ingredient. 25 He. Derivatives of Salicylic Acid The composition according to the invention comprises at least one compound chosen from salicylic acid and the derivatives of formula (III) below: in which: the radical Ra designates: an aliphatic chain having from 2 to 22 carbon atoms, saturated, linear, branched or cyclic; an unsaturated chain having 2 to 22 carbon atoms containing one or more conjugatable double bonds; an aromatic ring bonded to the carbonyl radical directly or via saturated or unsaturated aliphatic chains having from 2 to 7 carbon atoms; said groups being capable of being substituted by one or more substituents, which may be identical or different, chosen from: (a) halogen atoms, (b) trifluoromethyl group, (c) hydroxyl groups in free form or esterified with an acid having 1 to 6 carbon atoms, or (d) a carboxyl function in free form or esterified with a lower alcohol having 1 to 6 carbon atoms; Rb is a hydroxyl group; as well as their salts derived from a mineral or organic base.

According to one embodiment, the radical Ra designates: a saturated, linear, branched or cyclic aliphatic chain containing from 3 to 11 carbon atoms; or - an unsaturated chain containing from 3 to 17 carbon atoms and comprising one or more conjugated or non-conjugated double bonds; said hydrocarbon chains may be substituted with one or more substituents, identical or different, selected from: (a) halogen atoms; (b) trifluoromethyl group; (c) hydroxyl groups in free form or esterified with an acid having from 1 to 6 carbon atoms; or (d) a carboxyl function in free form or esterified with a lower alcohol having 1 to 6 carbon atoms; as well as their salts obtained by salification with a mineral or organic base. The more particularly preferred compounds are those in which the radical Ra is a C 1 -C alkyl group. Among the compounds of formula (III) which are particularly preferred, mention may be made of: n-octanoyl-5-salicylic acid (or capryloyl salicylic acid); n-decanoyl-5-salicylic acid; n-dodecanoyl-5-salicylic acid; n-heptyloxy-5-salicylic acid and their corresponding salts. The salicylic acid compound is preferably selected from salicylic acid and n-octanoyl-5-salicylic acid. More particularly, noctanoyl-5-salicylic acid will be used. N-octanoyl-5-salicylic acid (or capryloylsalicylic acid) is available under the name MEXORYL SABO by CH I MEX.

As examples of mineral bases, mention may be made of alkali metal hydroxides or alkaline earth metal hydroxides such as sodium hydroxide, potassium hydroxide or ammonia. Among the organic bases, mention may be made of amines and alkanolamines. Quaternary salts such as those described in patent FR 2 607 498 are particularly interesting. The compounds of formula (III) that can be used according to the invention are described in patents US 6,159,479, US 5,558,871, FR 2,581,542, FR 2,607,498, US 4,767,750, EP 378,936, US 5,267,407, US 5,667,789, US 5,580,549, and EP A- 570.230. According to one embodiment, the salicylic acid or the salicylic acid compound of formula (III) as described above is present in the composition according to the invention in an amount ranging from about 0.1% to about 5% by weight of active material (salicylic acid or derivative), relative to the total weight of the composition, preferably from about 0.1% to about 1% by weight of active ingredient, for example about 0.3% by weight active ingredient.30 IV. Acetyl 15-tetrapeptide: The composition according to the invention comprises the peptide N-acetyl-L-Tyrosyl-L-Prolyl L-Phenylalanyl-L-Phenylalaninamide or acetyl 15-tetrapeptide (INC1 name: ACETYL 5 TETRAPEPTIDE-15). Such a peptide is sold under the name SKINASENSYL® PW LS 9852 by the company Serobiological Laboratory (BASE). According to one embodiment, the acetyl 15-tetrapeptide is in the form of a powder in which it is present in an amount of 0.14% by weight, relative to the total weight of the powder, the rest being a mixture mannitol / sodium citrate, preferably at 89.86% / 10% proportions. According to one embodiment, the acetyl-15-tetrapeptide as described above is present in the composition according to the invention in an amount ranging from about 0.00005% to about 0.007% by weight of active material (acetyl 15-15). tetrapeptide), based on the total weight of the composition, preferably from about 0.0001% to about 0.003% by weight of active ingredient, for example about 0.0004% by weight of active ingredient. V. Grifola Frondosa Extract: An extract of the mushroom Grifola frondosa, also known as maitake, and its method of preparation are as described in WO 2002/02129. This extract is marketed under the name ETERNISKIN LS 9881® by Laboratoires Sérobiologiques and / or the company COGNIS. According to one embodiment, the Grifola frondosa extract is in the form of a powder in which the amount of the extract is 50% by weight relative to the total weight of the powder, the remainder being maltodextrin. An extract of Grifola frondosa as described above may be present in the composition according to the invention in an amount ranging from 0.005% to 0.5% by weight of active ingredient (Grifola frondosa), relative to the total weight of the composition , preferably ranging from 0.01% to 0.1% by weight of active material, and preferably ranging from 0.02% to 0.05% by weight of active material, for example about 0.03% by weight of material active. VI. Chlorella extract An extract of Chlorella and its preparation process are as described in application FR 2 747 922. It is more particularly a natural extract of algae of the Chlorella type, more particularly of a concentrated extract. Chlorella vulgaris marketed under the name DERMOCHLORELLA® by the company CODIF. According to one embodiment, the Chlorella extract is in the form of a solution in which it is present in an amount of 2.25% by weight relative to the total weight of the solution, the rest being a mixture of glycerine and water, preferably glycerin proportions 50 / water 47.75. An extract of Chlorella as described above may be present in the composition according to the invention in an amount ranging from 0.002% to 0.225% by weight of active ingredient (Chlorella), relative to the total weight of the composition, preferably from 0.012% to 0.12% by weight of active material, and preferably ranging from 0.008% to 0.035% by weight of active material, for example about 0.0225% by weight of active ingredient. According to one embodiment, the present invention relates to a cosmetic composition comprising: at least one C-glucoside derivative of formula (I) as described above in an amount of from about 1% to about 30%, by weight of active ingredient relative to the total weight of the composition; at least one phenoxypropionic acid derivative of formula (II) as described above in an amount of from about 0.1% to about 10% by weight of active ingredient relative to the total weight of the composition; at least salicylic acid or a compound of formula (III) as described above in an amount of from about 0.1% to about 5% by weight of active ingredient, relative to the total weight of the composition ; Acetyl 15-tetrapeptide in an amount ranging from about 0.00005% to about 0.007% by weight of active ingredient, based on the total weight of the composition; an extract of Grifola frondosa in an amount ranging from 0.005% to 0.5% by weight of active material, relative to the total weight of the composition; and an extract of Chlorella in an amount ranging from 0.002% to 0.225% by weight of active ingredient, based on the total weight of the composition, and a physiologically acceptable medium. According to one embodiment, the present invention relates to a cosmetic composition as defined above, characterized in that: the amount of C-glycoside derivative of formula (I) below: XR (I) with S, X and R such that defined above, is between 7% and 11% by weight of active material relative to the total weight of the composition; the amount of compound of the following formula (II): ## STR2 ## with Y and Ry as defined above, is between 0.5% and 1.5% by weight of active material relative to the total weight of the composition ; the amount of salicylic acid or of the following derivative of formula (III): embedded image in which R a and Rb are as defined above, is between 0.1% and 1% by weight; active material relative to the total weight of the composition; the amount of acetyl-tetrapeptide is between 0.0001% and 0.003% by weight of active material relative to the total weight of the composition; the amount of the Grifola frondosa extract is between 0.02% and 0.05% by weight of active ingredient relative to the total weight of the composition; and the amount of the Chlorella extract is between 0.008% and 0.035% by weight of active ingredient relative to the total weight of the composition.

VII. Additives: According to one embodiment, the composition according to the invention is in a physiologically acceptable medium. A physiologically acceptable medium is a non-toxic medium that can be applied to the skin and integuments of human beings and has a pleasant appearance, smell and feel. It can include water; organic solvents such as a C1-C8 alcohol, especially ethanol, isopropanol, tert-butanol, n-butanol; a polyol such as glycerine; a glycol such as butylene glycol, isoprene glycol, propylene glycol, polyethylene glycols such as PEG-8; polyol ethers, acetone, ethyl acetate. According to one embodiment, the composition further comprises at least one additive. The cosmetic composition may further comprise, as additive, at least one polymeric or non-polymeric hydrophilic or lipophilic thickener, a hydrophilic or lipophilic additive, an emulsifying agent, a stabilizing agent, a preservative, a filler that may be polymeric, a perfume, a odor absorber, an oil, a wax, a solvent, a colorant and / or a surfactant. The amounts of these various additives are those conventionally used in the cosmetics field, and for example vary from approximately 0.01% to 15% of the total weight of the composition. These additives, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into lipid spherules. As oils or waxes that may be used in the invention, mention may be made of mineral oils (liquid petroleum jelly), vegetable oils (liquid fraction of shea butter, sunflower oil, apricot oil), animal oils (perhydrosqualene), synthetic oils (Purcellin oil), silicone oils or waxes, also known as silicone derivatives (cyclomethicone, cyclopentasiloxane, cyclohexasiloxane) and fluorinated oils (perfluoropolyethers), beeswax, carnauba or paraffin waxes, or Shea Butter. To these oils can be added fatty alcohols (cetyl alcohol) and fatty acids (stearic acid). As emulsifiers that can be used in the invention, mention may be made, for example, of fatty acid esters of polyethylene glycol, esters of fatty acid and of polyol such as, glycerol linoleate, glycerol oleate, linolenate of glycerol, glycerol stearate and sorbitan tristearate, polysorbate 60 and the mixture of PEG-6 / PEG-32 / glycol stearate sold under the name Tefose 63 by the company Gattefosse.

As solvents that can be used in the invention, mention may be made of water, lower alcohols, in particular ethanol, isopropanol, and tert-butanol. According to one embodiment, the composition according to the invention comprises one or more additive (s) chosen (s) from among the following compounds: sodium hyaluronate (CRISTALHYAL® from Soliance); hydrophobically modified inulin (inulin lauryl carbamate) marketed under the name INUTEC SP1® from BENE () BIO BASED CHEMICALS; a mixture of organopolysiloxane and cyclohexasiloxane (13/87) (marketed under the name GRANSIL® RPS-D6 by Grant Industries); microspheres of copolymers of vinylidene chloride / acrylonitrile / methylmethacrylate expanded with isobutane (EXPANCEL® 551 DE 40 D42 from Expancel); thickening polymers; A fatty substance; a polyol such as glycerine; a glycol such as propylene glycol; sodium hydroxide; preservatives, for example disodium EDTA (ethylene diamine tetraacetic disodium acid); and solvents such as water and / or denatured alcohol. The composition may comprise water in sufficient quantity to reach 100% of the total weight of the composition. Preferably, the composition comprises at least 50% by weight of water relative to the total weight of the composition. According to a particular embodiment of the present invention, the cosmetic composition is intended for topical administration. For a topical application on the skin and / or on the integuments, the composition may have the form in particular of aqueous or oily solutions or of dispersions of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained By dispersing a fatty phase in an aqueous phase (HIE) or vice versa (W / O), or suspensions or emulsions of soft consistency of the cream or gel type aqueous or anhydrous, or microcapsules or microparticles, or dispersions vesicles of ionic and / or nonionic type or foams. According to one embodiment, the composition is in emulsion form. According to one embodiment, the composition is in the form of an oil-in-water emulsion. According to one embodiment, the composition is a serum. These compositions are prepared according to the usual methods. These cosmetic compositions may for example constitute creams for cleaning, protecting, treating or caring for the face, for the hands, for the feet, for large anatomical folds or for the body (for example, day creams, creams for night creams, make-up removing creams, foundation creams), fluid foundations, make-up removing milks, body protection or care milks, lotions, gels or mousses for skin care, such as lotions of cleaning, artificial tanning lotions.

The compositions may also be packaged in the form of an aerosol composition also comprising a propellant under pressure. The composition may be formulated in the form of an emulsion, cream, ointment, balm, milk, lotion, gel, mousse, solution or stick, preferably in the form of an emulsion.

The present invention also relates to a cosmetic process for the care of keratinous substances, in particular the skin, characterized in that a composition as defined above is applied to these so-called keratin materials. By "keratin materials" according to the invention is meant the skin, the body, the face and / or the eye contour, the lips, the nails, the mucous membranes, the eyelashes, the eyebrows, the hairs, the scalp and / or the hair, or any other skin area of the body. More particularly, the keratin materials according to the invention are the scalp, the hair, and / or the skin. Preferably the keratin materials according to the invention is the skin.

According to one embodiment, the method of cosmetic treatment of the skin comprises applying to the skin a composition as defined above to prevent, and / or reduce and / or correct the cutaneous dyschromias and / or to homogenize and / or lighten the complexion of the skin.

The various embodiments detailed above may be carried out separately or in combination with each other according to any of the possible combinations. The invention is illustrated by the following examples. The examples which follow serve to illustrate the invention without, however, being limiting in nature. The names are, as the case may be, in chemical names or International Cosmetic Ingredient Dictionary and Handbook (CTFA) names, and the percentages by weight unless otherwise indicated. EXAMPLES EXAMPLE Composition According to the Invention The composition according to the invention is prepared according to standard methods known to those skilled in the art.

The amounts are given as a percentage by weight relative to the total weight of the composition. Chemical Name / Trade Name Amount QSP 100 Water Preservatives 0.75 0.3 Acetyl 15-tetrapeptide SKINASENSYL® PW LS 9852 marketed by Serobiological Laboratories Polysilicone-11 (mixture of organopolysiloxane and cyclohexasiloxane (13)) / 87)) GRANSIL® RPS-D6 marketed by Grant Industries 0.335 Sodium hydroxide 1 Extract of Chlorella vulgaris DERMOCHLORELLA® marketed by CODIF Sodium hyaluronate CRISTALHYAL® marketed by Soliance 0.99 Thickening polymers 1 2- (4-hydroxyphenoxy) acid ) -propionic RADIANSKIN® PW LS 9918 marketed by Serobiological Laboratories 4 Propylene glycol 0.3 n-octanoyl-5-salicylic acid 0.75 Inulin lauryl carbamate INUTEC SP10 marketed by BENEO BIO BASED CHEMICALS 0.1 disodium EDTA 0.1 Copolymers d acrylates (micro-spheres of copolymers of vinylidene chloride / acrylonitrile / methylmethacrylate expanded with isobutane) EXPANCEL® 551 DE 40 D42 from Expancel 9 Cb Eta-D-xylopyranoside-2-hydroxy-propane MEXORYL SBB® from CHIMEX 0.06 Extract of Grifola frondosa ETERNISKIN® LS 9881 marketed by Laboratoires Sérobiologiques Fatty substances 6 0.3 Denatured alcohol MEXORYL SA130 from CHIMEX. Glycerine Example 2: Clinical Study on the Composition According to Example 1 1 - OBJECTIVES OF THE CLINICAL STUDY A clinical study was conducted on 50 Caucasian women with 2 applications on the face per day for 3 months of the composition according to Example 1. At the end of these 3 months, measurements were continued for 5 weeks in order to validate the persistence of the effects obtained. All evaluations were done on bare skin.

Spectrophotometric Measurements with Siascope® (SlAscope = Spectrophotometric Intracutaneous Analysis) This is a non-invasive instrumental method of quantifying the amount of melanin present in the skin. The measurements are based on the principle of spectral images. This method makes it possible to obtain representations of the amount of melanin in arbitrary units on the basis of gray levels. It makes it possible to calculate the area occupied by melanin on a precise area, and thus to determine the size of a pigmentary spot. - Measurements (n = 50) at OJ (D = Day), D28, D56 and D84 for the application period of the composition and D91, D98, D105, D112 and D119 for the afterglow period. - Analysis of the amount of melanin of a senile lentigo and adjacent skin areas (adjacent areas do not show pigment spots), contrast analysis between the senile lentigo and the adjacent skin area and calculation of the surface of the senile lentigo.

Photo Analysis Photographs of subjects in cross-polarized light (2 photos of 3/4, n = 50) at OJ, J28, J56, J84 for the application period of the composition and J91, J98, J105, J112 and J119 for the period of persistence were taken to evaluate: - The homogeneity of color (H76) and texture of the skin of the cheeks (Contrast and Entropy). - The color of the skin of the cheeks due to hemoglobin and melanin. 2 - POPULATION 50 women of Caucasian origin of phototype I to IV, aged between 40 and 65 years old, having any type of skin, 50% of whom have sensitive skin, presenting with pigmentary spots on the face with at least 1 senile lentigo ( well-defined task, of homogeneous color and greater than 3 mm in diameter), imperfections on the skin defined by a score higher on an ordinal scale of 1 to 9 for the following elements: dilated pores, inhomogeneity of the color and the skin texture and a dull complexion were selected. APPLICATION OF THE COMPOSITION Before the application of the composition according to Example 1, a "pre-treatment" of 2 weeks is carried out: the volunteers stop all use of their usual care and use a moisturizer, applied once a day in the evening on the face. This cream will be used throughout the study including during the afterglow period to ensure a constant level of skin hydration. The composition according to Example 1 was applied twice daily all over the face to replace the usual day cream of the subjects, and before the moisturizer in the evening, over a period of 12 weeks, by the subjects themselves. same.

The quantities applied correspond to the normal conditions of use for this type of product. After the end of the application of the composition according to Example 1, the moisturizer continued to be applied once a day in the evening for 5 weeks. 4 - EVALUATIONS 4,11 Statistics "Probability: - Comparison between all the points using ANOVA - Comparison between the point of interest and the starting point (JO) using the Dunett POST-HOC test Probability: - Comparison between J84, J81, J98, J105, J112 and J119 using ANOVA - Comparison between the point of interest and the discontinuation of the application of the composition (J84) using the Dunett POST-HOC test.

These analyzes were performed if the result of the Shapiro-Wilk normality test was less than 1%. Statistically significant probability: p <0.05 Probability close to significant: 0.05 É p <0.10 Not significant probability: pk 0.10 4.2 - Instrumental measurements with Siascope® 4.3 - Analysis of images in crossed polarized light 4.3.1- Acquisition of Photographs Photographs of the face (3/4 right and left view) in polarized cross-light were taken at different times with a Nikon D7000 high definition under standard and reproducible light conditions, thanks to the flash ( Elinchrom 600 RX - Switzerland). In order to ensure a good reproducibility, the pictures of the faces were taken with equipment that allows to keep the same position of the face and the camera in relation to each other and to reposition the volunteers precisely to each measurement time. 4.3.2 -Analysis of the images of the skin complexion The analysis of the color of the complexion consisted of the determination of the color of the right cheek and the left cheek. The variation in skin color is due to two main pigments: melanin and hemoglobin. The colors are classified by their nuance, brightness and saturation. Each color can be characterized in a geometric space where the coordinate axes can determine brightness, dominant tone, and saturation level. This approach is based on the interactions between light and the different textures of the skin. As a result, for each skin color, it can be determined what will be the new skin color if the amounts of hemoglobin or melanin are changed. 5 - RESULTS The results of the period of application were based on the complete tests at the end of the application period (J84) and the comparative analyzes were carried out compared to the starting point (OJ) whereas the results on persistence of effects were based on complete tests at the end of the study (J119) and analyzed in a comparative manner compared to J84 and OJ. 5.1 - Characteristics of the panel 59 subjects were included at the start of the study. The results of 53 subjects were analyzed during the application period of the composition (OJ, D28, J56 and J84) and 46 subjects during the afterglow period. The 46 subjects at the end of the study were between 44 and 65 years old (mean age 58.4 years). 5.2 - Measurements made with Siascope® 5.2.1 Color of the selected pigment spot (MH) Period of application of the composition: Color (MH) of the selected pigment spot (n = 53) Average and standard deviations (S) O J28 J56 J84 173.6 ± 20.0 187.5 ± 20.9 I <0.001 191.6 ± 19.0 <0.001 194.8 ± 23.1 <sky Percentage changes MH Variation% VS OJ J28 8.0 % J56 10.4% J84 12.2% Compared to the OG, the results show a significant increase in the gray tone of the pigmentary stain (HD) from 28 days (+ 8.0%) until the end of the application (+ 12.2%), thus showing that the composition has a significant brightening effect.

Effect remanence time: Color (MH) of the selected pigment spot (n = 46) Mean and standard deviations (Sd) OJ J84 J91 J98 J105 J112 J119 172.8 ± 20.1 193.8 ± 23.7 195, 2 ± 19.9 195.1 ± 19.2 <0.001 <D 0.6290 196.1 ± 20.4 192.4 ± 21.5 <0.0010 0.6560 195.7 ± 19.1 <0 0010 0.1770 <0.0010 0.6560 <0.0010 0.3520 Percentage changes MH Variation% VS OJ Variation% VS J84 J91 13.0% J98 12.9% - J105 13.2% J112 13.5 % J119 11.3% - The results show that the lightening of the pigmentary stain persists for 5 weeks following the application of the composition, with a significant increase in the MH parameter at any time compared to the beginning of the application and without significant evolution compared to the end of the application. 5.2.2 Skin color of the area adjacent to the pigment spot (MN) Period of application of the composition: Color (MN) of the selected adjacent area (n = 53) Mean and standard deviations (Sd) OJ J28 J56 J84 202.4 ± 15.6 211.6 ± 16.3 <0.001 213.2 ± 15.4 <0.001 216.8 ± 17.0 I <0.001 Percentage change MN Variation% VS OJ J28 4.6% J56 5, 3% J84 7.1% Compared with OJ, the results show a significant increase in the gray tone of the area adjacent to the pigment spot (MN) from 28 days (+ 4.6%) until the end of the (+ 7.1%), thus showing that the composition has a significant lightening effect. Effect remanence time: Color (MN) of the selected adjacent area (n = 46) Mean and standard deviations (Sd) OJ J84 J91 J98 J105 J112 J119 202.0 ± 15.9 216.0 ± 17.5 217, 0 ± 14.6 217.0 ± 14.8 <0.001 216.9 ± 15.0 217.5 ± 15.4 213.8 ± 16.5 <0.001 0.7420 <0.0010 <0 , 0010 <0,00100 0,7420 0,8250 0,4520 0,1340 Percentage changes MN Variation% VS OJ Variation% VS J84 J91 7.5% - J98 7.5% - J105 7.4% - J112 7 The results show that the lightening of the adjacent zone persists for 5 weeks following the application of the composition, with a significant increase in the MN parameter at any time compared to the beginning of the period. application and without significant change compared to the end of the application. 5.2.3 Color contrast between the pigment spot and the area adjacent to the pigment spot (C) 15 Application period of the composition: Color contrast (C) (n = 53) Mean and standard deviations (Sd) OJ J28 J56 J84 -28.8 ± 9.6 -24.1 ± 10.8 '<o, ocm -21.6 ± 11.5 <o, 00i -22.0 ± 11.0 <0.001 Percent changes C Variation % VS DO J28 -16.3% J56 -25.1% J84 -23.6% Compared with OJ, the results show a significant decrease in contrast at the gray tone (C) between the pigment spot and the area adjacent to the pigment spot from 28 days (-16.3%) to the end of the application (-23.6%), showing that the lightening effect is greater on the pigment spot than on the adjacent area and therefore , the pigmentary task becomes less visible. Effect retentivity time Color contrast (C) (n = 46) Mean and standard deviations (Sd) OJ J84 J91 J98 J105 J112 J119 21.9 ± 10.8 21.9 ± 10.4 21.3 ± 10, 21.4 ± 11.4 -21.4 ± 10.8 -29.2 ± 9.9 -22.2 ± 11.6 <o, 00 © <o, o io io <o, 00 io <o, ocio < cost) 0.996Cfl 1,000 (2) 0.650 © 0.502® 0.7360 Percent changes C Variation% VS OJ Variation% VS J84 J91 -25.0% - J98 -24.8% - J105 -27.1% - J112 - 26.7% - J119 -26.5% - The results show that the decrease in the contrast between the pigmentary stain and the skin persists for 5 weeks following the application of the composition, with a significant decrease in the parameter C at any time compared to the beginning of the application and without significant evolution compares to the end of the application. The pigmentary task therefore remains less visible during the period of stopping the application. 5.2.4 Surface of the selected pigment spot (S) Period of application of the composition: Area (S) of the selected pigment spot (n = 53) Average and standard deviations (Sd) OJ J28 J56 J84 4,614 ± 2,771 1,892 ± 2,076! <0.001 1.528 ± 2.40 <0.001 1.062 ± 1.433 1 <0.001 Percent change S% change VS OJ J28 -60.0% J56 -66.9% J84 -77.0% Compared to OJ, the results show a significant decrease in pigment surface area (S) from 28 days (-60.0%) to discontinuation of application (-77.0%), showing that the pigment spot is decreasing in area.

Effect remanence time: Area (S) of the selected pigment spot (n = 46) Mean and standard deviations (Sd) OJ J84 J91 J98 J105 J112 J119 0.873 ± 1.265 0.839 ± 1.074 1.239 ± 2.973 0.976 ± 1.320 1.461 ± 1.983 4.673 ± 2,888 1,164 ± 1,494 <0.0010 <0.0010 <0.0010 <0.00100 <0.00100 0.2850 0.2430 0.3380 0.5110 0.6590 Pot Variais.a. es S Variation% VS OJ Variation% VS J84 J91 -81.3% - J98 -82.1% - J105 -73.5% - J112 -79.1% - J119 -68.7% - The results show that the decrease in the surface of the pigmentary spot persists for 5 weeks following the application of the composition, with a significant decrease of the parameter S at any time compared to the beginning of the application and without significant evolution compared to the end of the application . 5.3 - Analysis of images in cross-polarized light: 5.3.3 Analogy of the color and texture texture of the water - Period of application of the composition: Average of the cheeks (right cheek and left cheek) - Application Average Delta p-value Variations raw data (%) N = 53 Average SD (Di-DO) OJ H76 3.48 0.39 Contrast 1.65 0.38 Entropy 4.92 0.22 D28 H76 3, 0.37 -0.12 ± 0.14 S; <0.0001 -3.57 Contrast 1.13 0.24 -0.53 ± 0.19 S; <0.0001 -31.87 Entropy 4.67 0.21 -0.25 ± 0.08 S; <0.0001 -5.05 J56 H76 3.29 0.37 -0.18 ± 0.15 S; <0.0001 -5.23 Contrast 1.06 0.19 -0.59 ± 0.22 S; <0.0001 -35.72 Entropy 4.63 0.20 -0.29 ± 0.08 S; <0.0001 -5.99 J84 H76 3.25 0.36 -0.23 ± 0.16 S; <0.0001 -6.47 Contrast 1.15 0.19 -0.50 ± 0.22 S; <0.0001 -30.14 Entropy 4.66 0.19 -0.26 ± 0.09 S; <0.0001 -5.23 Compared to OJ, after 28, 56 and 84 days of application, we observe on the cheeks: A significant decrease in H76 from 28 days (from -3.6% to -6, 5%), a significant decrease in contrast from 28 days (-31.9% to -30.1%), - A significant decrease in entropy from 28 days (from -5.1% to - 5.2%), The composition has a favorable effect on the homogeneity of color and texture of the skin, which becomes thinner on the cheeks and more regular appearance from 28 days of application.

Time of afterglow effects: Average of cheeks (right cheek and left cheek) - Retention of effects at J84 Average of APPLICATION Delta p-value Variations (%) raw data N = 46 Average SD (Di-D84) H76 3.24 0 , J84 Contrast 1.15 0.19 Entropy 4.66 0.19 H76 3.27 0.36 0.03 ± 0.19 NS; 0.855 0.98 J91 J98 J105 J112 Contrast 1.15 0.19 -0.004 ± 0.06 NS; 0.956 -0.39 Entropy H76 4.66 0.18 0.004 ± 0.06 NS; 0.999 NS, 0.992 0.08 3.22 0.35 -0.02 ± 0.14 -0.50 Contrast 1.14 0.19 -0.01 ± 0.05 NS; 0.290 -0.75 Entropy 4.66 0.19 -0.004 ± 0.07 NS; 0.999 NS; 0.944 -0.08 H76 3.22 0.35 -0.02 ± 0.14 -0.77 Contrast 1.14 0.19 -0.01 ± 0.05 NS; 0.956 -0.66 Entropy 4.65 0.19 -0.01 ± 0.06 NS; 0.769 NS; 1.000 -0.30 H76 3.23 0.35 -0.01 ± 0.14 -0.25 Contrast 1.16 0.20 0.01 ± 0.07 NS; 0.435 0.73 Entropy 4.67 0.18 0.01 ± 0.07 NS; 0.953 0.20 J119 H76 3.27 0.36 0.02 ± 0.15 NS; 0.947 0.76 Contrast 1.19 0.21 0.04 ± 0.08 NF; 0.003 3.40 Entropy 4.69 0.18 0.03 ± 0.08 NF; 0.028 0.69 Compared to the discontinuation of the application (J84), the results show that the effects on the cheeks persist after 5 weeks after stopping the application for color homogeneity and 4 weeks for homogeneity of texture of the skin. 5.3.4 -Distribution of hemoglobin (Hb) and melanin (lutes) Period of application of the composition: Average cheeks (right cheek and left cheek) - Application Average raw data APPLICATION Delta p-value Variations ( %) N = 53 SD average (Ti-TO) OD Hb color 35.33 2.82 Melanin color 31.67 6.57 J28 Hb color 35.45 2.59 0.12 ± 1.17 NS; 0.886 0.34 Melanine color 29.40 6.31 -2.27 ± 1.56 S; <0.0001 -7.18 J56 Hb color 35.08 2.62 -0.26 ± 1.38 NS; 0.407 -0.73 Melanin color 28.22 6.02 -3.45 ± 2.57 S; <0.0001 -10.90 J84 Hb color 34.86 2.36 -0.47 ± 1.34 S; 0.023 -1.34 Melanin color 27.50 5.48 -4.17 ± 2.8 S; <0.0001 -13.17 Compared to OJ, after 28, 56 and 84 days of application, the cheeks are observed: - A significant decrease in the color of the skin due to hemoglobin at 84 days (-1 , 3%), A significant decrease in skin color due to melanin from 28 days (from -7.2% to -13.2%), 4 The composition decreases the color of the skin on the cheeks due to hemoglobin after 84 days of application and decreases the color of the skin on the cheeks due to melanin from 28 days.

Effect afterglow time: Average of the cheeks (right cheek and left cheek) - Remaining effects at J84 Average raw data APPLICATION Delta p-value Variations (%) N = 46 Average SD (Ti- T12weeks) Hb color 34.88 2.34 J84 Color melanin Hb color 27.43 5.46 -0.12 ± 1.26 NS; 0.996 -0.34 J91 34.76 2.45 Melanin color 27.39 5.75 -0.04 ± 1.54 NS; 1,000 -0,14 J98 Hb color 34.81 2.57 -0.07 ± 1.15 NS; 1,000 -0,19 Color melanin Hb color 26.73 5.88 -0.70 ± 1.38 NS; 0.141 -2.55 34.81 2.34 -0.06 ± 1.09 NS; 1,000 -0.19 J105 26.34 5.70 -1.09 ± 1.48 S; 0.002 -3.97 Melanine color J112 Hb color 34.76 2.56 -0.12 ± 1.23 NS; 0.996 -0.34 J119 Melanin color 27.11 5.41 -0.32 ± 1.52 NS; 0.870 -1.18 Hb color 35.24 2.87 0.36 ± 1.69 NS; 0.648 1.03 Melanine color 26.99 5.76 -0.44 ± 1.83 NS; 0.647 -1.60 Compared to the discontinuation of the application (J84), the results show that the decrease in the color of the skin of the cheeks due to hemoglobin and melanine persists for 5 weeks after stopping the application. 6 - CONCLUSIONS Under the experimental conditions, the composition according to the invention of Example 1 showed on the subjects tested: Instrumental measurements with Siascope® - senile Lentigo and its adjacent zone (without pigment spot): Compared to OJ, one observed a significant increase in the gray tone of the senile lentigo (MH) and its adjacent zone (MN), associated with a decrease in contrast (C); showing a lightening effect of the composition according to Example 1 on the lentigo and its adjacent zone, making the lentigo less visible. e Compared to OJ, a significant decrease in the area (S) of the lentigo was observed from 28 days of application; showing a decrease in the size of the lentigo. Compared with J84, no significant change in parameters (MH, MN, C, and S) was observed showing the persistence of the lightening effect for 5 weeks after the end of the application. Analysis of images in crossed polarized light: - Homogeneity of color and texture of the skin: - Compared to OJ, a significant decrease in H76 was observed and in the parameters "Contrast" and "Entropy" from 28 days on cheeks; showing a homogeneous color of the skin and a finer and more regular texture of the skin. Compared to J84, a residual effect of the composition was observed for a homogeneous skin color up to 5 weeks. - Distribution of hemoglobin and melanin: - Compared with JO, for the cheeks, a significant decrease in the color of the skin due to hemoglobin was observed at J84 and a significant decrease in the color of the skin due melanin was observed on D28. Staining of the complexion due to hemoglobin and melanin has been reduced. Compared with J84, a residual effect of the composition on the color of the complexion was observed for 5 weeks after stopping the application.

Claims (13)

REVENDICATIONS1. A composition comprising: a) at least one C-glycoside derivative of the following general formula (I): X-R (I) wherein: R is an unsubstituted C1-C4 linear alkyl radical; S represents a monosaccharide selected from D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose; X represents a group chosen from -CO-, -CH (OH) -, -CH (NH 2) -; and their isomers and mixtures thereof; b) at least one compound of the following formula (II): embedded image in which: Y is chosen from H, an alkyl or alkenyl group comprising from 1 to 8 carbon atoms, a phenyl, Na, e or NH4 +; Ry is chosen from H, a linear or branched, saturated or unsaturated alkyl group comprising from 1 to 18 carbon atoms, a -C (= O) -Rz group, in which Rz is a linear or branched, saturated or unsaturated alkyl group; Comprising from 1 to 17 carbon atoms or a group - (CH2), - COORw in which n is between 0 and 17, Rw is chosen from H, an alkyl or alkenyl group comprising from 1 to 8 carbon atoms, a phenyl, Na +, e or NH4 + or one of its organic or inorganic base salts, or one of its enantiomers; c) at least salicylic acid or a derivative of the following formula (11): Rb in which: the radical Ra designates: an aliphatic chain containing 2 to 22 carbon atoms, saturated, linear, branched or cyclic; an unsaturated chain having 2 to 22 carbon atoms containing one or more conjugatable double bonds; an aromatic ring bonded to the carbonyl radical directly or via saturated or unsaturated aliphatic chains having from 2 to 7 carbon atoms; said groups may be substituted by one or more substituents, which may be identical or different, chosen from: (i) halogen atoms, (ii) trifluoromethyl group, (iii) hydroxyl groups in free form or esterified with an acid having 1 to 6 carbon atoms, or (iv) a carboxyl function in free form or esterified with a lower alcohol having 1 to 6 carbon atoms; - Rb is a hydroxyl group; or one of its salts derived from a mineral or organic base; d) acetyl 15-tetrapeptide; e) an extract of Grifola frondosa; and f) an extract of Chlorella. 2. Composition according to claim 1, wherein the compound of formula (I) is C-beta-D-xylopyranoside-2-hydroxy-propane. 3. Composition according to claim 1 or 2, wherein the compound of formula (II) is 2- (4-hydroxy-phenoxy) -propionic acid. 4. Composition according to any one of claims 1 to 3, wherein the compound of formula (III) is n-octanoyl-5-salicylic acid. The cosmetic composition of claim 1 comprising: C-beta-D-xylopyranoside-2-hydroxypropane; - (4-hydroxy-phenoxy) -propionic acid; n-octanoyl-5-salicylic acid; acetyl 15-tetrapeptide; - an extract of Grifola frondosa; an extract of Chlorella vulgaris; and a physiologically acceptable medium. 15 6. Cosmetic composition according to any one of claims 1 to 5, characterized in that the amount of said derivative C-glycoside of formula (I) is between 7% and 11% by weight of active ingredient relative to the total weight composition; The amount of said compound of formula (II) is between 0.5% and 1.5% by weight of active material relative to the total weight of the composition; the amount of salicylic acid or said derivative of formula (III) is between 0.1% and 1% by weight of active material relative to the total weight of the composition; the amount of acetyl-tetrapeptide is between 0.0001% and 0.003% by weight of active material relative to the total weight of the composition; the amount of the Grifola frondosa extract is between 0.02% and 0.05% by weight of active ingredient relative to the total weight of the composition; and the amount of the Chlorella extract is between 0.008% and 0.035% by weight of active ingredient relative to the total weight of the composition. 30 7. Cosmetic use of the composition according to any one of claims 1 to 6, for improving the homogeneity of the complexion and / or lightening the complexion. 8. Cosmetic use according to claim 7, for preventing and / or reducing and / or correcting cutaneous dyschromias. 9. Cosmetic use according to claim 8, for lightening and / or reducing the surface of cutaneous dyschromias. 10. Cosmetic use according to one of claims 8 or 9, wherein the dyschromias are selected from the tasks of hyperpigmentation and redness. 11. Use according to claim 7 for refining the skin texture and / or reducing and / or correcting surface irregularities of the skin. The use according to any one of claims 7 to 11, wherein said composition is for topical administration. 13. Cosmetic process for the care of keratinous substances, in particular the skin, characterized in that a composition as defined according to any one of Claims 1 to 6 is applied to these keratin materials.